Mystery San Diego party inks $300m deal with Abzena for antibody linking tech

By Dani Bancroft contact

- Last updated on GMT

Mystery San Diego party inks $300m deal with Abzena for ADC tech

Related tags: License

An unnamed San Diego-based firm has signed a licensing agreement for Abzena Plc’s ThioBridge antibody drug conjugate (ADC) linker technology.

ThioBridge is a platform which links antibodies and other proteins to drugs, to help maintain stability of the antibody and a consistent Drug-to-Antibody Ratio​ (DAR), which reduces risk of unwanted side effects.

The unidentified firm will be the fifth private party to license Abzena’s linker technologies, with the deal allowing for use of ThioBridge​ on up to 10 ADCs across a range of indications.

“Abzena and the US biopharmaceutical company has enjoyed an ongoing collaborative research programme to evaluate ThioBridge up until now,” ​said John Burt, CEO of Abzena.

“The collaboration has allowed both parties to build a strong working relationship and to demonstrate the value of the ThioBridge technology in creating novel ADCs.”

This new deal could potentially earn Abzena over $300 million, including milestone payments, with further earnings on sales royalties of any approved products using the technology.

The firm’s share prices jumped over 62% in response to the news.

Feature Image: iStock/Goir

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us

Products

View more

Webinars